Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Suresh S. Ramalingam, MD
Emory University, Atlanta, Georgia, United States of America.
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
283 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Research Site
Birtinya, Australia
Recruiting - Research Site
Blacktown, Australia
Withdrawn - Research Site
Clayton, Australia
Recruiting - Research Site
Gosford, Australia
Recruiting - Research Site
Melbourne, Australia
Withdrawn - Research Site
South Brisbane, Australia
Recruiting - Research Site
Wodonga, Australia
Recruiting
- Research Site
Innsbruck, Austria
Recruiting - Research Site
Krems, Austria
Recruiting - Research Site
Linz, Austria
Recruiting - Research Site
Rankweil, Austria
Recruiting - Research Site
Vienna, Austria
Recruiting - Research Site
Vienna, Austria
Recruiting - Research Site
Wels, Austria
Recruiting
- Research Site
Anderlecht, Belgium
Withdrawn - Research Site
Bruges, Belgium
Recruiting - Research Site
Hasselt, Belgium
Recruiting - Research Site
La Louvière, Belgium
Recruiting - Research Site
Liège, Belgium
Recruiting
- Research Site
Barretos, Brazil
Recruiting - Research Site
Curitiba, Brazil
Recruiting - Research Site
Florianópolis, Brazil
Recruiting - Research Site
Ipatinga, Brazil
Recruiting - Research Site
Natal, Brazil
Recruiting - Research Site
Porto Alegre, Brazil
Recruiting - Research Site
Rio de Janeiro, Brazil
Recruiting - Research Site
Santa Maria, Brazil
Recruiting - Research Site
São Paulo, Brazil
Recruiting - Research Site
Taubaté, Brazil
Recruiting
- Research Site
Vancouver, British Columbia, Canada
Recruiting - Research Site
Winnipeg, Manitoba, Canada
Withdrawn - Research Site
St. John's, Newfoundland and Labrador, Canada
Recruiting - Research Site
London, Ontario, Canada
Recruiting - Research Site
Newmarket, Ontario, Canada
Withdrawn - Research Site
Oshawa, Ontario, Canada
Recruiting - Research Site
Toronto, Ontario, Canada
Withdrawn - Research Site
Lévis, Quebec, Canada
Recruiting - Research Site
Montreal, Quebec, Canada
Recruiting - Research Site
Montreal, Quebec, Canada
Recruiting - Research Site
Montreal, Quebec, Canada
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 11 Apr 2024
- Primary completion
- 28 Dec 2029
- Completion
- 28 Dec 2029
- Last update posted
- 16 Jun 2026
- Registered enrollment
- 675
- Registry id
- NCT06357533
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.